People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Pharmaceuticals, Biotechnology, Other Health Care, Healthtech, Software / Tech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Catabasis Pharmaceuticals Inc | — | Pharmaceuticals | Series D+ | $349.6M | $3.3B | 2010 |
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $494.8M | 2016 |
| Xilio Therapeutics, Inc. | — | Biotechnology | Series C | $145.2M | $3.0B | 2021 |
| Therini Bio, Inc. | — | Biotechnology | Series C | $84.2M | $1.1B | 2019 |
| Abcam plc | — | Other Health Care | Series C | $79.6M | $18.3M | 2012 |
| Link Medicine Corp | — | Biotechnology | Series B | $64.8M | $190.8M | 2008 |
| Ophthotech Corp. | — | Biotechnology | Series B | $43.1M | $452.5M | 2018 |
| TRex Holdings Inc. | — | Biotechnology | Series C | $42.3M | $329.3M | 2024 |
| Avitide, Inc. | — | Pharmaceuticals | Series A | $40.9M | $309.7M | 2013 |
| Dualitas Therapeutics, Inc. | — | Biotechnology | Series B | $32.6M | $150.2M | 2025 |
| Lucina Health, Inc. | — | Healthtech | Seed | $24.0M | $50.1M | 2009 |
| Ribometrix, Inc. | — | Pharmaceuticals | Series A | $18.5M | $464.6M | 2018 |
| Juvaris Bio Therapeutics Inc | — | Biotechnology | Series B | $15.9M | $29.8M | 2009 |
| NICE Recovery Systems LLC | — | Software / Tech | Seed | $5.9M | $16.4M | 2019 |
| Maine Crisp Company, LLC | — | Other | Seed | $1.1M | $18.0M | 2020 |
| Fresco Foods, Inc. | — | Agtech / Foodtech | Pre-Seed | $720K | $10.8M | 2017 |
| Andovia Inc. | — | Other Technology | Pre-Seed | $632K | $6.6M | 2023 |
| Balance Health Corp | — | Other | Pre-Seed | $500K | $11.6M | 2010 |
Michael Ross at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Ross on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Guyer | 2 | 8 |
| Tillman Gerngross | 2 | 5 |
| Claudio Nessi | 2 | 5 |
| Daniel Burgess | 2 | 4 |
| Michael L. Ross | 2 | 3 |
| Michael C. Ross | 2 | 3 |
| Nikola Trbovic | 2 | 3 |
| Nicholas C. Galakatos | 2 | 3 |
| Rene Russo | 2 | 2 |
| Carl Gordon | 1 | 24 |
| DAVID GARDNER | 1 | 20 |
| Ajay Royan | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| Robert Weisskoff | 1 | 12 |
| Joshua Resnick | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Timothy Petersen | 1 | 9 |
| Terrance McGuire | 1 | 9 |
| Wright Steenrod | 1 | 9 |
| Joel Marcus | 1 | 9 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.